Program: RRPV

Solicitation Number: RPP 24-02-OralVx

Customer: BARDA

Release Date:  09/09/2024

Submission Deadline: 11/15/2024 1PM ET

Description: BARDA is requesting project proposals from developers to advance next generation oral vaccine formulations and technologies for COVID-19 into proof-of-concept Phase 1 trials. Oral delivery of vaccines offers several potential benefits for pandemic preparedness over traditional needle/syringe-based delivery, including: ease of administration from the perspective of both those administering vaccines and people receiving vaccines; generation of mucosal immunity at the site of infection; potential for reduced cold chain reliance; and improved distribution and administration logistics.

active_solicitations

solicitation_program: RRPV

solicitation_number: RPP-24-02

solicitation_customer: BARDA

solicitation_release_date: 09/09/2024

solicitation_submission_deadline: 11/15/2024 1PM ET

solicitation_description:  BARDA is requesting project proposals from developers to advance next generation oral vaccine formulations and technologies for COVID-19 into proof-of-concept Phase 1 trials. Oral delivery of vaccines offers several potential benefits for pandemic preparedness over traditional needle/syringe-based delivery, including: ease of administration from the perspective of both those administering vaccines and people receiving vaccines; generation of mucosal immunity at the site of infection; potential for reduced cold chain reliance; and improved distribution and administration logistics.

solicitation_url: https://www.rrpv.org/solicitation/nextgen-oral-formulation-vaccines-for-covid-19/